Search
for
Sort by
Research 151–180 of 187
- Efficacy of Local and Whole‐Body Phototherapy for the Treatment of Various Types of Alopecia Areata
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Alopecia areata: current concepts
- Approach to Managing Recalcitrant Alopecia Areata with Combination Therapy: A Series of Five Cases in Black Pediatric Patients
- Comparative analysis of therapeutic outcomes in pediatric versus adult ophiasis-pattern alopecia areata: A review of treatment modalities and disease course
- When JAK inhibitors are off the table: durable remission of severe alopecia areata with dexamethasone oral mini-pulse and a focused review
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Comparison of Current International Guidelines for the Management of Alopecia Areata—Comprehensive Review
- Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies
- Dual Relief: How Atopic Dermatitis Treatments Affect Alopecia Areata—A Small Retrospective Cohort Study
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
- An Updated in the Management of Alopecia Areata
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Quality of life in children and adolescents with alopecia areata—A systematic review
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Serum Level of Macrophage Migration Inhibitory Factor (MIF) in Egyptians With Alopecia Areata and Its Relation to the Clinical Severity of the Disease
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Possible role of β‐hydroxybutyrate in inducing inflammation in alopecia areata
- Cosmeceutical and Dermatological Potential of Olive Mill Wastewater: A Sustainable and Eco-Friendly Source of Natural Ingredients
- Altered hypothalamus functional connectivity and psychological stress in patients with alopecia areata
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- A Pilot Randomized Controlled Trial Comparing the Efficacy and Safety of Oral Tofacitinib Versus Methotrexate In Moderate-to-Severe Alopecia Areata
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review